Fundraising Fox
/Companies
Sign in

4TEEN4 Pharmaceuticals GmbH

Hennigsdorf, DE · Founded 2013 · 37 employees on LinkedIn · 2 known investors

Find your way into 4TEEN4 Pharmaceuticals GmbH

Sign up to find every way you can get introduced to 4TEEN4 Pharmaceuticals GmbH

  • Your email: who you already know at 4TEEN4 Pharmaceuticals GmbH, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the 4TEEN4 Pharmaceuticals GmbH team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

4TEEN4 develops monoclonal antibody therapeutics targeting shock and critical illness in patients. The company is advancing invobenitug (procizumab), a first-in-class treatment designed to address circulating dipeptidyl peptidase 3, a molecular driver of cardiovascular dysfunction and organ failure in shock states.

BiotechHealthtechMedical Devices

Founders & leadership

4TEEN4 Pharmaceuticals GmbH was founded in 2013 by Dr. Andreas Bergmann and Dr. Joachim Struck.

DADr. Andreas Bergmann
Dr. Andreas BergmannCEO
DJDr. Joachim Struck
Dr. Joachim StruckCRO
DK
Dr. Karine BourgeoisCSO
PMProf. Mahir Karakas
Prof. Mahir KarakasCMO
DK
Dr. Kilian von SeldeneckCFO
DCDr. Chris Springer
Dr. Chris SpringerCOO

Investors · 2

Görlich Gruppelisted by Görlich GruppeBerlin

How we know: Görlich Gruppe's portfolio page · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

4TEEN4 Extends Series C Financing Round to €55 Million, Supporting Expanded Clinical Development of Procizumab in Cardiogenic Shockglobenewswire.com · Nov 2025Biotech Startup 4TEEN4 Pharmaceuticals Closes EUR 7 Million Series A Financingfinance.yahoo.com · Dec 2019

Frequently asked questions

What does 4TEEN4 Pharmaceuticals GmbH do?
4TEEN4 develops monoclonal antibody therapeutics targeting shock and critical illness in patients. The company is advancing invobenitug (procizumab), a first-in-class treatment designed to address circulating dipeptidyl peptidase 3, a molecular driver of cardiovascular dysfunction and organ failure in shock states.
Who founded 4TEEN4 Pharmaceuticals GmbH?
4TEEN4 Pharmaceuticals GmbH was founded by Dr. Andreas Bergmann, Dr. Joachim Struck in 2013.
Who are 4TEEN4 Pharmaceuticals GmbH's investors?
4TEEN4 Pharmaceuticals GmbH's investors include Brandenburg Kapital, Görlich Gruppe.
Where is 4TEEN4 Pharmaceuticals GmbH headquartered?
4TEEN4 Pharmaceuticals GmbH is headquartered in Hennigsdorf, DE.